arrow
F

Fang-Shu Ou

Mayo Clinic
H指数:46
被引数:9,589

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer

激活内吞通路对结直肠癌亚型和治疗敏感性的分层作用

2026-10-190
OAAI
Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

II期研究: futibatinib联合pembrolizumab治疗FGF19表达型晚期肝细胞癌患者的疗效观察

2026-08-250
OAAI
Optimized dose schedule of rucaparib and liposomal irinotecan/5-fluorouracil in metastatic gastrointestinal cancers: A phase 1 study

rucaparib和脂质体伊立替康/5-氟尿嘧啶在转移性消化道肿瘤中的优化给药方案:一项1期研究

Cancer
IF5.1
2025-11-220
PRE
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study

一线阿替利珠单抗/贝伐珠单抗或度伐利尤单抗/特瑞普利单抗在晚期肝细胞癌中的应用:一项真实世界、多中心回顾性研究

2025-11-010
PRE
Feasibility of Non-Operative Management Following Neoadjuvant Immune Checkpoint Inhibitors in Resectable dMMR/MSI-H Gastroesophageal Adenocarcinoma

新辅助免疫检查点抑制剂治疗后可切除dMMR/MSI-H胃肠腺癌的非手术管理可行性

2025-10-010
PRE
GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer

2025-08-240
OAAI
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: a combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)

FOLFIRI联合贝伐珠单抗或西妥昔单抗在奥沙利铂为基础辅助治疗患者中的疗效:FIRE-3和CALGB/SWOG 80405 (Alliance)联合分析

2025-08-050
PRE
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
2024-04-011
PRE
Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405
2022-08-205
PRE
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis
2022-05-013
OA
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
2021-11-027
OA